FN2 Earnings Intelligence
Sanofi earnings overview
Latest Sanofi (SNY) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Sanofi
Sanofi’s Q3 analysis supports the view that sustained Dupixent demand and newer launches are underpinning growth: management reported 14% sales growth and raised 2026 guidance. The durability of that trajectory remains contingent on managing Dupixent’s coming loss of exclusivity, pricing and gross-to-net pressures, and pipeline execution.
Sanofi
Sanofi’s raised 2026 outlook and expanded long-term ambitions reflect confidence in Dupixent, newer product launches and operating leverage. Whether that growth is durable depends on execution across the pipeline and R&D transformation, while the Regeneron relationship and tougher comparisons remain important risks.
Get the SNY recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.